Abstract

An isotope adsorbent of the present invention may comprise a base portion, pore channels formed as a plurality of holes in the base portion, first and second sorption sites positioned at a wall portion of each pore channel, and a third sorption site positioned in the central portion of the pore channel. An isotope separation method of the present invention may comprise the steps of: injecting an isotope mixture including a first element and a second element into an isotope adsorbent; allowing the first element or the second element to be adsorbed onto wall portions of the pore channels of the isotope adsorbent; and, when the second element, having a greater mass than the first element, is adsorbed onto the wall portions of the pore channels, allowing the second element to be further adsorbed onto the inside of the adsorbed second element.

IPC Classes  ?

• B01D 59/26 - Separation by extracting by sorption, i.e. absorption, adsorption, persorption
• B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material

Abstract

The present invention relates to a biomarker composition for diagnosing exposure to fine dust, a detection method therefor, and a method for diagnosing exposure to fine dust by using same, and, more specifically, it was ascertained that a 2-naphthol level in urine increase as exposure to fine dust increases, so that a change in the 2-naphthol level in urine reflects exposure to polycyclic aromatic hydrocarbons, which is one of the main components of Korean fine dust, and thus a biomarker for diagnosing exposure to fine dust and identifying exposure amount can be provided. It was ascertained that a sample pretreatment process and an HPLC/FLD analysis condition according to the present invention resolve convenience and economic feasibility problems of conventional analysis methods so as to that a change in 1-naphthol or 2-naphthol level in non-invasive samples and urine is more accurately detected, and thus the sample pretreatment process and the HPLC/FLD analysis condition can be provided as a method for diagnosing exposure to fine dust.

IPC Classes  ?

• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
• G01N 30/74 - Optical detectors
• G01N 30/72 - Mass spectrometers
• G01N 30/06 - Preparation

Abstract

Lactobacillus acidophilusStreptococcus thermophilusStreptococcus thermophilus strains in a medium for intestinal beneficial bacteria and is substantially equivalent to fructooligosaccharide and galactooligosaccharide, which are representative prebiotics, in terms of functions thereof, and thus a prebiotic composition containing a pear extract as an active ingredient, a synbiotic composition comprising the prebiotic composition, and a functional food composition comprising the synbiotic composition are provided.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23P 10/20 - AgglomeratingGranulatingTabletting

Abstract

The present invention relates to a method for providing information for the early diagnosis of colon cancer by using a biological sample in order to diagnose colon cancer. More specifically, excellent quantification of PhIP and MeIQx in terms of yield is achieved when a biological sample of urine is hydrolyzed with a strong alkali and then analyzed through liquid extraction, as compared to when the sample is hydrolyzed with an enzyme or a strong acid. Thus, a method that uses a strong alkali for hydrolyzing a sample and then liquid extraction may be provided as a diagnosis method for the effective and non-invasive early diagnosis of colon cancer using a biological sample.

IPC Classes  ?

• G01N 30/72 - Mass spectrometers
• G01N 30/06 - Preparation
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups

Abstract

The present invention relates to a biomarker composition for predicting the prognosis or determining the stage of chronic liver disease. The present invention performs a total RNA-seq analysis on tissues of patients with steatosis and non-alcoholic steatohepatitis, and identifies 38 genes that are specifically highly expressed during disease progression from steatosis to non-alcoholic steatohepatitis. The present invention selects genes showing a characteristic expression pattern, and constructs a classification model capable of distinguishing between steatosis and non-alcoholic steatohepatitis using the genes. As a result, the present invention verifies that steatosis and non-alcoholic steatohepatitis can be classified with high accuracy. Accordingly, the genes may be used as biomarkers for predicting the prognosis of chronic liver disease or as biomarkers for classifying steatosis and non-alcoholic steatohepatitis, and development of gene therapy or other drugs that inhibit the expression or activity of the genes may improve the effectiveness of treating chronic liver disease.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a survey-based wellness analysis system and a method therefor. According to the present invention, a wellness analysis method using a survey-based wellness analysis system comprises the steps of: receiving responses from users with respect to a wellness survey divided into eight areas; calculating area-specific total scores and exposure scores by adding response scores for each area; calculating a wellness score by using the area-specific total scores; and analyzing the degree of wellness by using the calculated area-specific total scores and wellness score, and providing the analyzed result to a user who has filled out the survey. According to the present invention, the degree of exposure of each user to a harmful substance can be checked on the basis of the survey divided into eight areas, and a solution that is suitable to the user can be provided by using the checked degree of exposure.

IPC Classes  ?

• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

Abstract

The present invention relates to a music output apparatus using a sensor and a method thereof. According to the present invention, the music output apparatus using the sensor comprises: a sensor unit including any one of a pressure sensor, a gyro sensor, and an acceleration sensor; a gesture recognition unit for recognizing a user's gesture by using sensed data; a controller for changing pre-stored music or generating new music corresponding to the recognized gesture; and an output unit for outputting the changed music or the generated music. As described above, the music output apparatus using the sensor according to an embodiment of the present invention can be used for music therapy without constructing expensive equipment, and enables music to be easily produced and arranged, thereby arousing the interest of infants. In addition, people majoring in music can conveniently practice in perfect pitch or give an improvised performance while carrying the music output apparatus using the sensor according to an embodiment of the present invention.

IPC Classes  ?

• G10H 1/00 - Details of electrophonic musical instruments
• G10G 1/02 - Chord or note indicators, fixed or adjustable, for keyboards or fingerboards

Abstract

The present invention relates to a fluorescent probe for detecting NAD(P)H in mitochondria, and a detection method using same. A probe of the present invention exhibits high selectivity and sensitivity to NAD(P)H and emits strong red fluorescence in the presence of NAD(P)H. Therefore, the probe exhibits predominant accumulation in the mitochondria of living cells, is usable in the detection and quantification of NAD(P)H in the mitochondria, and can provide a selective image of the mitochondria in real time, thereby being effectively usable for biological pathway studies and the identification of pathological diagnoses and the like. In addition, the present invention can be used to differentiate cancer cells from normal cells on the basis of mapping of the intensity of NAD(P)H-dependent fluorescence in mitochondria.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 21/76 - ChemiluminescenceBioluminescence
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/483 - Physical analysis of biological material
• C07D 221/12 - Phenanthridines
• G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C07C 381/00 - Compounds containing carbon and sulfur and having functional groups not covered by groups

Abstract

The present invention relates to a method for preparing choline alfoscerate, usable as a food raw material, from phosphatidylcholine or lecithin, and a choline alfoscerate preparation method according to the present invention uses a specific reaction medium and a specific catalytic enzyme, thereby enabling a high purity choline alfoscerate to be effectively prepared. Particularly, the preparation method allows a mixed solvent of water and hexane, which have high substrate solubility and an extraction solvent usable in the preparation of food raw materials, to be used as a reaction medium, and enables high purity purification of choline alfoscerate by only using a layer separation process of the reaction medium, thereby enhancing the productivity of choline alfoscerate to be greater than that of a conventional enzymatic synthesis method, having, unlike a conventional chemical synthesis method and a conventional purification method, very simple purification, and enabling the preparation of choline alfoscerate which is usable as a food raw material. Specifically, lecithin is a raw material of fractionated lecithin used as a substrate in the preparation method and is an inexpensive raw material obtained as a by-product in a soybean oil refining process and the like, and thus is expected to be greatly helpful in the commercialization of the preparation method in the future. In addition, choline alfoscerate prepared by the method according to the present invention can be effectively usable as a material for foods, pharmaceuticals and the like for improving cognitive function in patients having had a stroke and having dementia such as Alzheimer's disease.

IPC Classes  ?

• C12P 13/00 - Preparation of nitrogen-containing organic compounds
• C12N 9/20 - Triglyceride splitting, e.g. by means of lipase
• C12N 11/04 - Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
• C12N 11/08 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen

Abstract

The present invention relates to a foreign language learning system, and a method for providing a foreign language learning service by using the same. The method for providing a foreign language learning service by using a foreign language learning system, according to the present invention, comprises the steps of: requesting, from a user terminal, an input of at least one piece of data for each of personal information data, environmental information data and context information data when a request for providing a foreign language learning sentence is received from the user terminal; grouping, by classification, the at least one piece of inputted data so as to generate a plurality of data groups, and using the inputted data so as to analyze a current situation of a user; extracting a plurality of hyponyms and a sentence pattern corresponding to the current situation from among a plurality of hyponyms and a plurality of sentence patterns included in a database; randomly selecting a word included in the extracted synonyms and the grouped data so as to insert the selected word into a place holder location of the extracted sentence pattern, and using a seed modular random algorithm so as to generate a final sentence; and providing the generated final sentence to the user terminal. The present invention can simultaneously provide a vivid foreign language learning service optimized to a user and induce interest in the user such that the user voluntarily learns a foreign language.

IPC Classes  ?

• G06Q 50/20 - Education
• G09B 19/06 - Foreign languages
• G06F 17/00 - Digital computing or data processing equipment or methods, specially adapted for specific functions

Abstract

The present invention relates to the use of teosinte branched 1, cycloidea and PCF transcription factors (TCPs) in shade avoidance. The present inventors confirmed that TCP proteins, such as TCP5, TCP13, and TCP17, are involved in shade avoidance through interaction with ATHB2, HAT3, and ATHB4. In addition, a plant in which TCP13 is overexpressed expresses genes necessary for a shade avoidance response although it is cultured in a normal condition, but not in a shade condition, which indicates that TCP13 is a main upstream regulator giving rise to a shade avoidance response in a shade condition. That is, as described above, the investigation of a role of TCP13 in shade avoidance may be usefully applied to the expansion of productivity and yield of crops.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a composition containing an ANKS1A protein expression or activation inhibitor as an active ingredient for preventing or treating cancer, and a method for screening for the composition, and by means of the present invention, a composition having a superb cancer prevention and treatment effect and a method allowing convenient screening of an anti-cancer agent can be provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided is a pharmaceutical composition for preventing or treating muscular dystrophy containing Psoralea corylifolia-derived bakuchiol as an active ingredient. The pharmaceutical composition is effective for stimulating myocyte regeneration and inducing differentiation into myocytes.

IPC Classes  ?

• A61K 36/487 - Psoralea
• A61K 31/05 - Phenols

Abstract

The present invention relates to a biomarker composition for diagnosing the sensitivity to an anticancer agent in anticancer agent-resistant breast cancer, a diagnosis kit, a diagnosis method, or a pharmaceutical composition for promoting anticancer effects, wherein it is possible to help effective treatment of tumors by restoring the sensitivity to anticancer agents such as tamoxifen, etc. if the expression of LY6K is inhibited or miR-192-5p is suppressed in breast cancer cells. Also, it is possible to help effective treatment of tumors by restoring the sensitivity to anticancer agents such as tamoxifen, etc. if the expression of miR-500a-3p is induced or miR-500a-3p is applied in breast cancer cells.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines

Abstract

The present invention relates to a pharmaceutical composition for treating STK11-mutation cancer, containing, as an active ingredient, a material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1); an anticancer drug containing the composition as an active ingredient; and a method for screening STK11-mutation cancer therapeutic agent. It was first established that, of cancer cells in which various gene mutations are confirmed, an STK11-mutation cancer cell line, which is confirmed at high frequency, was treated with cardiac glycosides as a material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1), to significantly inhibit the growth of cancer cells. Therefore, the material inhibiting a sodium-potassium transport function of Na+-K+ ATPase (ATP1A1) can be a target for treating STK11-mutation-derived cancer.

IPC Classes  ?

• A61K 31/558 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to novel peptides and use thereof and more specifically is directed to a peptide with anti-inflammatory effect, a polynucleotide encoding the peptide, a pharmaceutical composition comprising the peptide or polynucleotide for preventing or treating inflammatory diseases, an anti-inflammatory drug, an over-the-counter (OTC) drug composition comprising the peptide for preventing or ameliorating inflammation, a health food composition for alleviating or ameliorating inflammation, a cosmetic composition for preventing or ameliorating inflammation, a method for treating inflammatory diseases, comprising administrating the pharmaceutical composition to the subject suspected of having inflammatory disease, a method for preparing a mimetic of the peptide and a method for designing the same.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/09 - Tripeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
• C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
• C07K 5/072 - Dipeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
• C07K 5/068 - Dipeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
• A23L 1/305 - Amino acids, peptides or proteins 
• C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

In order to determine epigenetic variations of autosomal dominant polycystic kidney disease and functional association therebetween, the present inventors have subjected individuals with polycystic kidney disease and without polycystic kidney disease to analysis through methylation profiling in random fashion of the genome as a whole. Interestingly, in PKD1 and other genes associated with ion transport and cell adhesion, there was hypermethylation in the gene-body region, and the expression of these genes was down-regulated in polycystic kidney disease. In particular, in PKD1, there was hypermethylation in the polycystic kidney disease gene-body region, and this was associated with MBD2 (methyl-CpG-binding domain 2) protein binding. In addition, DNA methylation inhibitor treatment was accompanied by up-regulation of PKD1 expression and caused a delay in cyst formation in MDCK (Madin-Darby Canine Kidney) cells. This therefore demonstrates that, in the present invention, hypermethylation of PKD1 and regulator genes associated with cyst formation plays a decisive role in cyst formation and shows that the present invention can be used in therapeutic applications for autosomal dominant polycystic kidney disease.

IPC Classes  ?

• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention relates to novel peptides and use thereof and more specifically is directed to a peptide with anti-inflammatory effect, a polynucleotide encoding the peptide, a pharmaceutical composition comprising the peptide or polynucleotide for preventing or treating inflammatory diseases, an anti-inflammatory drug, an over-the-counter (OTC) drug composition comprising the peptide for preventing or ameliorating inflammation, a health food composition for alleviating or ameliorating inflammation, a cosmetic composition for preventing or ameliorating inflammation, a method for treating inflammatory diseases, comprising administrating the pharmaceutical composition to the subject suspected of having inflammatory disease, a method for preparing a mimetic of the peptide and a method for designing the same.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a novel use of erythroid differentiation regulator 1 (Erdrl) as an agent for treating cancer. More particularly, it relates to an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and inhibiting cancer metastasis, an use of Erdrl or an expression vector including a polynucleotide encoding the same for preventing and treating cancer, an use of an antibody specific for Erdrl for diagnosing cancer, or a method for screening agents for regulating cancer metastasis or cancer cells migration. The Erdrl is negatively regulated by IL-18 expression and it suppresses migration, invasion and metastasis of cancer or tumor cell by expression of HSP90 and generation of ROI. And an Erdrl recombinant protein promotes NK-cell killing activity against cancer cell. Accordingly, the Erdrl and an expression vector comprising polynucleotide encoding the same and recombinant protein suppress cancer metastasis and bring an effect on activation of immune cells, and therefore can be useful for preventing, treating and diagnosing cancer.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial-skin and preparation of blood vessels for transplantation.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 27/00 - Drugs for disorders of the senses

Abstract

The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• C07K 11/00 - Depsipeptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to an adipocyte differentiation medium composition and a method of differentiating preadipocytes into adipocytes using the same. The adipocyte differentiation medium composition is characterised in that it comprises insulin, DHEA (dehydroepiandrosterone) and histamine. Said medium composition achieves smoother distribution and more stable settling of differentiated adipocytes in comparison with conventional adipocyte differentiation medium compositions, thereby maximising adipocytic cell viability. Furthermore, the DHEA and histamine used in said medium composition is more cost-efficient than conventional adipocyte differentiation medium compositions that rely on dexamethasone and isobutylmethylxanthine.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Disclosed herein is a method for producing a cyst-expressed transgenic animal using a PKD2 gene. The production method comprises preparing a PKD2 protein expression vector, inserting the expression vector into the nucleus of a fertilized egg to produce a PKD2 expression vector-containing fertilized egg, and transplanting the produced fertilized egg into the uterus of a surrogate mother. According to the invention disclosed herein, there is provided a method for producing transgenic animals, in which cysts are expressed only by the over express ion of the PKD2 gene. Also, transgenic mice are provided which can be effectively used in the investigation of cyst expression mechanisms and cyst control systems.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates